DVA vs NKTR · P/E 14, rev $6.97B vs rev $21.0M
DaVita HealthCare Partners Inc (DVA) versus Nektar Therapeutics (NKTR) — a side-by-side from cached financials, not a winner call.
DaVita HealthCare Partners Inc (DVA) is a medical care facilities company listed on US.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Latest reported DVA revenue for 2026-06-30 was $6.97B. Net income was $462.9M. DVA currently screens at market cap $10.77B and trailing P/E 14.1.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
DVA currently screens at market cap $10.77B and trailing P/E 14.1. NKTR currently screens at market cap $307.2M.
Not investment advice. Open the DVA and NKTR stock pages for the full models.
Not investment advice.